UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 204

Sortiert nach

Metabolic Perturbance in Autism Spectrum Disorders: A Metabolomics Study

Journal of proteome research, 2012-12, Vol.11 (12), p.5856-5862

2012

Link zum Volltext

Verfügbarkeit prüfen

Inflammation and resolution are associated with upregulation of fatty acid β-oxidation in Zymosan-induced peritonitis

PloS one, 2013-06, Vol.8 (6), p.e66270

2013

Link zum Volltext

Verfügbarkeit prüfen

The Effects of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines in Vitro and in Vivo

Molecular cancer therapeutics, 2001-12, Vol.1 (2), p.85-94

2001

Link zum Volltext

Verfügbarkeit prüfen

KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism

PloS one, 2015-12, Vol.10 (12), p.e0144825-e0144825

2015

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches

Supportive care in cancer, 2004-08, Vol.12 (8), p.543

2004

Link zum Volltext

Verfügbarkeit prüfen

Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

Cancer research (Chicago, Ill.), 2008-04, Vol.68 (7), p.2366-2374

2008

Link zum Volltext

Verfügbarkeit prüfen

Inflammation and Resolution Are Associated with Upregulation of Fatty Acid [beta]-Oxidation in Zymosan-Induced Peritonitis.(Research Article)

PloS one, 2013-06, Vol.8 (6), p.e66270

2013

Link zum Volltext

Verfügbarkeit prüfen

2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles

Bioorganic & medicinal chemistry letters, 2010-01, Vol.20 (2), p.679-683

2010

Link zum Volltext

Verfügbarkeit prüfen

2,3,5-Trisubstituted pyridines as selective AKT inhibitors—Part I: Substitution at 2-position of the core pyridine for ROCK1 selectivity

Bioorganic & medicinal chemistry letters, 2010-01, Vol.20 (2), p.673-678

2010

Link zum Volltext

Verfügbarkeit prüfen

Constitutive mutants of the protein kinase STE11 activate the yeast pheromone response pathway in the absence of the G protein

Genes & development, 1992-07, Vol.6 (7), p.1293-1304

1992

Link zum Volltext

Verfügbarkeit prüfen

STE11 is a protein kinase required for cell-type-specific transcription and signal transduction in yeast

Genes & development, 1990-11, Vol.4 (11), p.1862-1874

1990

Link zum Volltext

Verfügbarkeit prüfen

Defective G2 checkpoint function in cells from individuals with familial cancer syndromes

Cancer research (Chicago, Ill.), 1995-04, Vol.55 (8), p.1763-1773

1995

Link zum Volltext

Verfügbarkeit prüfen

A simple method for predicting serum protein binding of compounds from IC50 shift analysis for in vitro assays

Bioorganic & medicinal chemistry letters, 2004-05, Vol.14 (9), p.2309-2312

2004

Link zum Volltext

Verfügbarkeit prüfen

A simple method for predicting serum protein binding of compounds from IC(50) shift analysis for in vitro assays

Bioorganic & medicinal chemistry letters, 2004-05, Vol.14 (9), p.2309-2312

2004

Link zum Volltext

Verfügbarkeit prüfen

A simple method for predicting serum protein binding of compounds from IC 50 shift analysis for in vitro assays

Bioorganic & medicinal chemistry letters, 2004-05, Vol.14 (9), p.2309-2312

2004

Link zum Volltext

Verfügbarkeit prüfen

Expression and Purification of Active Recombinant ATM Protein from Transiently Transfected Mammalian Cells

Protein expression and purification, 2001-08, Vol.22 (3), p.462-466

2001

Link zum Volltext

Verfügbarkeit prüfen

Defective potassium currents in ataxia telangiectasia fibroblasts

Genes & development, 1998-12, Vol.12 (23), p.3686-3692

1998

Link zum Volltext

Verfügbarkeit prüfen

Deregulation of specific E2F complexes by the v-mos oncogene

Oncogene, 1997-06, Vol.14 (25), p.3029-3038

1997

Link zum Volltext

Verfügbarkeit prüfen

Serum starved v-mos-transformed cells are unable to appropriately downregulate cyclins and CDKs

Oncogene, 1997-06, Vol.14 (25), p.3017-3027

1997

Link zum Volltext

Verfügbarkeit prüfen

Molecular Mechanisms of Environmental Carcinogenesis

Environmental health perspectives, 1995-05, Vol.103 (5), p.504-506

1995

Link zum Volltext

Verfügbarkeit prüfen

v-mos-Transformed Cells Fail to Enter Quiescence but Growth Arrest in G1 Following Serum Withdrawal

Experimental cell research, 1994-07, Vol.213 (1), p.210-217

1994

Link zum Volltext

Verfügbarkeit prüfen

A yeast- Escherichia coli shuttle vector containing the M13 origin of replication

Plasmid, 1990-03, Vol.23 (2), p.159-162

1990

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 204

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(176)
Mit Volltextzugriff
(178)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Metabolic Perturbance in Autism Spectrum Disorders: A Metabolomics Study

Inflammation and resolution are associated with upregulation of fatty acid β-oxidation in Zymosan-induced peritonitis

The Effects of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines in Vitro and in Vivo

KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism

Identification of 4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a Novel Inhibitor of AKT Kinase

Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches

Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

Inflammation and Resolution Are Associated with Upregulation of Fatty Acid [beta]-Oxidation in Zymosan-Induced Peritonitis.(Research Article)

2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles

2,3,5-Trisubstituted pyridines as selective AKT inhibitors—Part I: Substitution at 2-position of the core pyridine for ROCK1 selectivity

Constitutive mutants of the protein kinase STE11 activate the yeast pheromone response pathway in the absence of the G protein

STE11 is a protein kinase required for cell-type-specific transcription and signal transduction in yeast

Defective G2 checkpoint function in cells from individuals with familial cancer syndromes

Identification of 4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3 S )-3-piperidinylmethyl]oxy}-1 H -imidazo[4,5- c ]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a Novel Inhibitor of AKT Kinase

A simple method for predicting serum protein binding of compounds from IC50 shift analysis for in vitro assays

Identification of 4-2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-([(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a Novel Inhibitor of AKT Kinase

A simple method for predicting serum protein binding of compounds from IC(50) shift analysis for in vitro assays

A simple method for predicting serum protein binding of compounds from IC 50 shift analysis for in vitro assays

Expression and Purification of Active Recombinant ATM Protein from Transiently Transfected Mammalian Cells

Defective potassium currents in ataxia telangiectasia fibroblasts

Deregulation of specific E2F complexes by the v-mos oncogene

Serum starved v-mos-transformed cells are unable to appropriately downregulate cyclins and CDKs

Molecular Mechanisms of Environmental Carcinogenesis

v-mos-Transformed Cells Fail to Enter Quiescence but Growth Arrest in G1 Following Serum Withdrawal

A yeast- Escherichia coli shuttle vector containing the M13 origin of replication

Suchergebnisse filtern